Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
MAIA Biotechnology, Inc. ( (MAIA) ) has provided an update.
On September 11, 2025, MAIA Biotechnology announced positive efficacy data from its THIO-101 Phase 2 clinical trial, which evaluates ateganosine (THIO) in combination with the immune checkpoint inhibitor cemiplimab for advanced non-small cell lung cancer patients. The trial showed promising results, with a median progression-free survival of 5.6 months, significantly surpassing the standard of care threshold of 2.5 months, and a median overall survival of 17.8 months. Two patients completed 33 cycles of therapy, indicating potential for extended dosing and longer survival. The trial’s findings suggest that ateganosine could enhance and prolong immune response in patients who have failed previous treatments, potentially impacting MAIA’s positioning in the cancer treatment market.
The most recent analyst rating on (MAIA) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on MAIA Biotechnology, Inc. stock, see the MAIA Stock Forecast page.
Spark’s Take on MAIA Stock
According to Spark, TipRanks’ AI Analyst, MAIA is a Neutral.
MAIA Biotechnology presents a mixed outlook. The company’s financial performance is weak due to its development-stage status and lack of revenue, contributing to a low financial performance score. However, recent positive trial results and technical indicators showing short-term upward momentum provide a more optimistic view. Valuation remains challenging due to negative earnings, but the potential for significant clinical advancements offers upside potential.
To see Spark’s full report on MAIA stock, click here.
More about MAIA Biotechnology, Inc.
MAIA Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer. The company is engaged in the development and commercialization of potential first-in-class drugs with novel mechanisms of action, particularly focusing on ateganosine (THIO), a cancer telomere targeting agent for the treatment of non-small cell lung cancer (NSCLC) patients with telomerase-positive cancer cells.
Average Trading Volume: 436,678
Technical Sentiment Signal: Sell
Current Market Cap: $51.47M
For detailed information about MAIA stock, go to TipRanks’ Stock Analysis page.